XORTX Therapeutics Inc, formerly APAC Resources Inc, is Canada-based biopharmaceutical Company. The Company focuses on developing therapies to treat progressive kidney disease. XORTX Therapeutics Inc has programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. Its development programs focus on potential treatments for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Diabetic Nephropathy (DN). Its pipeline products: Autosomal Dominant Polycystic Kidney Disease is in Phase II clinical trial, Diabetic Nephropathy is in Phase I clinical trial, and NASH is in the pre-clinical stage.